Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.45 |
| ▸ | GSK3A | P49840 | 1/20 | 0.45 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.45 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.43 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30431594 | 1.00 | CHEK1 (0.45) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| Hydrochloric Acid SCHEMBL2481630 | 0.98 | MPO (0.44) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL20769904 | 0.87 | CHEK1 (0.41) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL378619 | 0.84 | CHEK1 (0.57) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL30006507 | 0.84 | CHEK1 (0.57) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| Pyrazole SCHEMBL28207901 | 0.83 | CYP1A2 (0.40) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL5343977 | 0.82 | CHEK1 (0.56) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL20769975 | 0.80 | HTR2A (0.50) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL217944 | 0.79 | HTR2A (0.45) | CHEK1AURKADAPK3CSNK1A1GSK3A | |
| SCHEMBL31039602 | 0.79 | HTR2A (0.45) | CHEK1AURKADAPK3CSNK1A1GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3416948-B1 | INDACENE BEARING SULFONYLUREAS AS ANTI-INFLAMMATORY AGENTS | UNIV QUEENSLAND (AU) | 2024-07-24 | — | — | EP | claimed |
| US-20100152167-A1 | PYRIMIDINE DERIVATIVES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | claimed |
| US-7709480-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-04 | — | — | US | claimed |
| EP-1438053-B1 | PYRIMIDINE DERIVATIVES, PHARMACEUTICAL AGENT CONTAINING SAID COMPOUNDS, USE AND METHOD FOR MAKING SAME | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-09-10 | — | — | EP | claimed |
| US-7173028-B2 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-02-06 | — | — | US | claimed |
| US-20060100211-A1 | Pyrimidine derivatives | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-05-11 | — | — | US | claimed |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-09-11 | — | — | US | claimed |
| EP-0904769-B1 | Keratin fibre dye compositions containing Indazole amine derivatives and dyeing method | OREAL (FR) | 2002-09-25 | — | — | EP | claimed |
| US-6027538-A | OXIDATION DYEING OF KERATINOUS FIBERS CONTAINING AT LEAST ONE COUPLER SELECTED FROM INDAZOLEAMINE DERIVATIVES AND AT LEAST ONE OXIDATION BASE; POWERFUL, NOT VERY SELECTIVE HAIR DYES WHICH ARE CAPABLE OF GENERATING INTENSE COLOR | L'OREAL S.A. (FR) | 2000-02-22 | — | — | US | claimed |
| EP-4724443-A1 | PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE | Acrivon Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2025-08-26 | — | — | US | disclosed |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | ARTIOS PHARMA LIMITED (GB) | 2025-07-15 | — | — | US | disclosed |
| US-6027538-A | OXIDATION DYEING OF KERATINOUS FIBERS CONTAINING AT LEAST ONE COUPLER SELECTED FROM INDAZOLEAMINE DERIVATIVES AND AT LEAST ONE OXIDATION BASE; POWERFUL, NOT VERY SELECTIVE HAIR DYES WHICH ARE CAPABLE OF GENERATING INTENSE COLOR | L'OREAL S.A. (FR) | 2000-02-22 | — | — | US | disclosed |
| EP-0047328-B1 | 1H AND 2H INDAZOLE DERIVATIVES AND MEDICAMENT CONTAINING THEM | SIEGFRIED AKTIENGESELLSCHAFT (CH) | 1984-05-09 | — | — | EP | disclosed |
| US-4436913-A | HYPOTENSIVE AGENTS | SIEGFRIED AKTIENGESELLSCHAFT (CH) | 1984-03-13 | — | — | US | disclosed |
| WO-1982000824-A1 | 1H AND 2H INDAZOL DERIVATIVES AND MEDICAMENTS CONTAINING THEM | GEISSMANN F | 1982-03-18 | — | — | WO | disclosed |
| EP-0047328-A1 | 1H and 2H indazole derivatives and medicament containing them | SIEGFRIED AKTIENGESELLSCHAFT (CH) | 1982-03-17 | — | — | EP | disclosed |
| US-4006127-A | Cationic diazacyanine dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100211-A1 | Pyrimidine derivatives | TYMP, TYMS, DPYD | CHEK1 409/4885AURKA 1005/4885DAPK3 3001/4885 |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | ABL1, TH, CYP3A43 | CHEK1 4372/4885AURKA 2230/4885DAPK3 1169/4885 |
| US-20030171359-A1 | Suitable for treatment of illnesses characterised by excessive or abnormal cell proliferation; viral, bacterial, fungal and/or parasitic infections, skin diseases, bone diseases, cardiovascular diseases | COL1A1, MKI67, INSR | CHEK1 3237/4885AURKA 1385/4885DAPK3 3551/4885 |
| US-20100152167-A1 | PYRIMIDINE DERIVATIVES | TYMP, TYMS, DPYD | CHEK1 409/4885AURKA 1005/4885DAPK3 3001/4885 |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | KRAS, NRAS, HRAS | CHEK1 371/4885AURKA 1408/4885DAPK3 1021/4885 |
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | CHEK1 84/4885AURKA 1089/4885DAPK3 1512/4885 |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | SDHA, DPYD, TP53 | CHEK1 77/4885AURKA 455/4885DAPK3 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.